Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:55 PM
Ignite Modification Date:
2025-12-24 @ 4:55 PM
NCT ID:
NCT03951350
Eligibility Criteria:
Inclusion criteria:
* Individuals over the age of 18.
* Both sexes.
* Having a duration of depression symptoms of at least 2 months.
* Who perfectly understand written and spoken Spanish.
* Who have provided their informed consent.
Exclusion criteria:
* Suffering from another disease that affects the central nervous system (organic brain pathology or having suffered a traumatic brain injury of any severity, dementia).
* Having another psychiatric diagnosis or serious psychiatric illness (substance dependence or abuse, history of schizophrenia or other psychotic disorders, eating disorders) with the exception of anxious pathology or personality disorders (collected through a medical history and from the Mini-International Neuropsychiatric Interview (MINI) (Ferrando, Bobes, \& Gibert, 2000)).
* Presence of a serious or uncontrolled medical, infectious or degenerative illness that may interfere with the affective symptoms.
* Presence of delirium or hallucinations, risk of suicide, pregnancy or lactation.
* Patients who have participated in another clinical trial over the past 6 months or who are currently in psychotherapy.
* Who practice mindfulness, yoga, meditation or similar practices over the past 6 months, engaging in formal practice at least once a week.
* Presence of any medical, psychological or social problem that could seriously interfere with the patient's participation in the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03951350
Study Brief:
Protocol Section:
NCT03951350